External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in speci...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2023-05, Vol.41 (15), p.2736-2746
Hauptverfasser: Halabi, Susan, Yang, Qian, Roy, Akash, Luo, Bin, Araujo, John C, Logothetis, Christopher, Sternberg, Cora N, Armstrong, Andrew J, Carducci, Michael A, Chi, Kim N, de Bono, Johann S, Petrylak, Daniel P, Fizazi, Karim, Higano, Celestia S, Morris, Michael J, Rathkopf, Dana E, Saad, Fred, Ryan, Charles J, Small, Eric J, Kelly, William Kevin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2746
container_issue 15
container_start_page 2736
container_title Journal of clinical oncology
container_volume 41
creator Halabi, Susan
Yang, Qian
Roy, Akash
Luo, Bin
Araujo, John C
Logothetis, Christopher
Sternberg, Cora N
Armstrong, Andrew J
Carducci, Michael A
Chi, Kim N
de Bono, Johann S
Petrylak, Daniel P
Fizazi, Karim
Higano, Celestia S
Morris, Michael J
Rathkopf, Dana E
Saad, Fred
Ryan, Charles J
Small, Eric J
Kelly, William Kevin
description We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in specific subgroups (White, Black, Asian patients, different age groups, and specific treatments) and to classify patients into validated two and three prognostic risk groupings on the basis of the model. Data from 8,083 docetaxel-naïve mCRPC men randomly assigned on seven phase III trials were used to validate the prognostic model of OS. We assessed the predictive performance of the model by computing the time-dependent area under the receiver operating characteristic curve (tAUC) and validated the two-risk (low and high) and three-risk prognostic groups (low, intermediate, and high). The tAUC was 0.74 (95% CI, 0.73 to 0.75), and when adjusting for the first-line androgen receptor (AR) inhibitor trial status, the tAUC was 0.75 (95% CI, 0.74 to 0.76). Similar results were observed by the different racial, age, and treatment subgroups. In patients enrolled on first-line AR inhibitor trials, the median OS (months) in the low-, intermediate-, and high-prognostic risk groups were 43.3 (95% CI, 40.7 to 45.8), 27.7 (95% CI, 25.8 to 31.3), and 15.4 (95% CI, 14.0 to 17.9), respectively. Compared with the low-risk prognostic group, the hazard ratios for the high- and intermediate-risk groups were 4.3 (95% CI, 3.6 to 5.1; < .0001) and 1.9 (95% CI, 1.7 to 2.1; < .0001). This prognostic model for OS in docetaxel-naïve men with mCRPC has been validated using data from seven trials and yields similar results overall and across race, age, and different treatment classes. The prognostic risk groups are robust and can be used to identify groups of patients for enrichment designs and for stratification in randomized clinical trials.
doi_str_mv 10.1200/JCO.22.02661
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10414709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2800149509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-fca65740283464633a597f640c6c953d2d1f87145acd3c106f932474f662007f3</originalsourceid><addsrcrecordid>eNpVkctuFDEQRS0EIkNgxxp5yYIe_Hb3CqFWeERJBvHeWcZtZ4x67IntaZGP4Fv4CH4s7slDsLJV9_hWuS4ATzFaYoLQy-N-tSRkiYgQ-B5YYE5kIyXn98ECSUoa3NLvB-BRzj8Rwqyl_CE4oBIxxDu2AL-PfhWbgh7hVz36QRcfA4wOavghxfMQc_EGnsbBjnN1NdmkxxF-2qXJT_WRD_DUBvjNlzXs13YTy7oS28vmTP_9M9kqFp2Lnk36ekl7_-ajzb5WQ5mbzLKtajA2PQYPnB6zfXJzHoIvb44-9--ak9Xb9_3rk8bQlpfGGS24ZIi0lAkmKNW8k04wZITpOB3IgF0rMePaDNRgJFxHCZPMCVE3Jh09BK-ufbe7Hxs7GBvqaKPaJr_R6VJF7dX_SvBrdR4nhRHDTKKuOjy_cUjxYmdzURufjR1HHWzcZUXaedsd36MvrlFTP5uTdXd9MFJzhKpGqAhR-wgr_uzf2e7g28zoFcoBmYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2800149509</pqid></control><display><type>article</type><title>External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Halabi, Susan ; Yang, Qian ; Roy, Akash ; Luo, Bin ; Araujo, John C ; Logothetis, Christopher ; Sternberg, Cora N ; Armstrong, Andrew J ; Carducci, Michael A ; Chi, Kim N ; de Bono, Johann S ; Petrylak, Daniel P ; Fizazi, Karim ; Higano, Celestia S ; Morris, Michael J ; Rathkopf, Dana E ; Saad, Fred ; Ryan, Charles J ; Small, Eric J ; Kelly, William Kevin</creator><creatorcontrib>Halabi, Susan ; Yang, Qian ; Roy, Akash ; Luo, Bin ; Araujo, John C ; Logothetis, Christopher ; Sternberg, Cora N ; Armstrong, Andrew J ; Carducci, Michael A ; Chi, Kim N ; de Bono, Johann S ; Petrylak, Daniel P ; Fizazi, Karim ; Higano, Celestia S ; Morris, Michael J ; Rathkopf, Dana E ; Saad, Fred ; Ryan, Charles J ; Small, Eric J ; Kelly, William Kevin</creatorcontrib><description>We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in specific subgroups (White, Black, Asian patients, different age groups, and specific treatments) and to classify patients into validated two and three prognostic risk groupings on the basis of the model. Data from 8,083 docetaxel-naïve mCRPC men randomly assigned on seven phase III trials were used to validate the prognostic model of OS. We assessed the predictive performance of the model by computing the time-dependent area under the receiver operating characteristic curve (tAUC) and validated the two-risk (low and high) and three-risk prognostic groups (low, intermediate, and high). The tAUC was 0.74 (95% CI, 0.73 to 0.75), and when adjusting for the first-line androgen receptor (AR) inhibitor trial status, the tAUC was 0.75 (95% CI, 0.74 to 0.76). Similar results were observed by the different racial, age, and treatment subgroups. In patients enrolled on first-line AR inhibitor trials, the median OS (months) in the low-, intermediate-, and high-prognostic risk groups were 43.3 (95% CI, 40.7 to 45.8), 27.7 (95% CI, 25.8 to 31.3), and 15.4 (95% CI, 14.0 to 17.9), respectively. Compared with the low-risk prognostic group, the hazard ratios for the high- and intermediate-risk groups were 4.3 (95% CI, 3.6 to 5.1; &lt; .0001) and 1.9 (95% CI, 1.7 to 2.1; &lt; .0001). This prognostic model for OS in docetaxel-naïve men with mCRPC has been validated using data from seven trials and yields similar results overall and across race, age, and different treatment classes. The prognostic risk groups are robust and can be used to identify groups of patients for enrichment designs and for stratification in randomized clinical trials.</description><identifier>ISSN: 0732-183X</identifier><identifier>ISSN: 1527-7755</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.22.02661</identifier><identifier>PMID: 37040594</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Docetaxel - therapeutic use ; Humans ; Male ; ORIGINAL REPORTS ; Prognosis ; Proportional Hazards Models ; Prostatic Neoplasms, Castration-Resistant - pathology ; Treatment Outcome</subject><ispartof>Journal of clinical oncology, 2023-05, Vol.41 (15), p.2736-2746</ispartof><rights>2023 by American Society of Clinical Oncology 2023 American Society of Clinical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-fca65740283464633a597f640c6c953d2d1f87145acd3c106f932474f662007f3</citedby><cites>FETCH-LOGICAL-c385t-fca65740283464633a597f640c6c953d2d1f87145acd3c106f932474f662007f3</cites><orcidid>0000-0001-5308-8972 ; 0000-0003-2986-5617 ; 0000-0001-7012-1754 ; 0000-0002-6068-9474 ; 0000-0002-2034-595X ; 0000-0003-4135-2777 ; 0000-0003-2629-672X ; 0000-0002-9454-0096 ; 0000-0001-6165-5797 ; 0000-0003-3938-2627 ; 0000-0002-8102-288X ; 0000-0002-3983-5676 ; 0000-0003-3191-6268 ; 0000-0002-3782-7226</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887,3731,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37040594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Halabi, Susan</creatorcontrib><creatorcontrib>Yang, Qian</creatorcontrib><creatorcontrib>Roy, Akash</creatorcontrib><creatorcontrib>Luo, Bin</creatorcontrib><creatorcontrib>Araujo, John C</creatorcontrib><creatorcontrib>Logothetis, Christopher</creatorcontrib><creatorcontrib>Sternberg, Cora N</creatorcontrib><creatorcontrib>Armstrong, Andrew J</creatorcontrib><creatorcontrib>Carducci, Michael A</creatorcontrib><creatorcontrib>Chi, Kim N</creatorcontrib><creatorcontrib>de Bono, Johann S</creatorcontrib><creatorcontrib>Petrylak, Daniel P</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Higano, Celestia S</creatorcontrib><creatorcontrib>Morris, Michael J</creatorcontrib><creatorcontrib>Rathkopf, Dana E</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Ryan, Charles J</creatorcontrib><creatorcontrib>Small, Eric J</creatorcontrib><creatorcontrib>Kelly, William Kevin</creatorcontrib><title>External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in specific subgroups (White, Black, Asian patients, different age groups, and specific treatments) and to classify patients into validated two and three prognostic risk groupings on the basis of the model. Data from 8,083 docetaxel-naïve mCRPC men randomly assigned on seven phase III trials were used to validate the prognostic model of OS. We assessed the predictive performance of the model by computing the time-dependent area under the receiver operating characteristic curve (tAUC) and validated the two-risk (low and high) and three-risk prognostic groups (low, intermediate, and high). The tAUC was 0.74 (95% CI, 0.73 to 0.75), and when adjusting for the first-line androgen receptor (AR) inhibitor trial status, the tAUC was 0.75 (95% CI, 0.74 to 0.76). Similar results were observed by the different racial, age, and treatment subgroups. In patients enrolled on first-line AR inhibitor trials, the median OS (months) in the low-, intermediate-, and high-prognostic risk groups were 43.3 (95% CI, 40.7 to 45.8), 27.7 (95% CI, 25.8 to 31.3), and 15.4 (95% CI, 14.0 to 17.9), respectively. Compared with the low-risk prognostic group, the hazard ratios for the high- and intermediate-risk groups were 4.3 (95% CI, 3.6 to 5.1; &lt; .0001) and 1.9 (95% CI, 1.7 to 2.1; &lt; .0001). This prognostic model for OS in docetaxel-naïve men with mCRPC has been validated using data from seven trials and yields similar results overall and across race, age, and different treatment classes. The prognostic risk groups are robust and can be used to identify groups of patients for enrichment designs and for stratification in randomized clinical trials.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Docetaxel - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>ORIGINAL REPORTS</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prostatic Neoplasms, Castration-Resistant - pathology</subject><subject>Treatment Outcome</subject><issn>0732-183X</issn><issn>1527-7755</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkctuFDEQRS0EIkNgxxp5yYIe_Hb3CqFWeERJBvHeWcZtZ4x67IntaZGP4Fv4CH4s7slDsLJV9_hWuS4ATzFaYoLQy-N-tSRkiYgQ-B5YYE5kIyXn98ECSUoa3NLvB-BRzj8Rwqyl_CE4oBIxxDu2AL-PfhWbgh7hVz36QRcfA4wOavghxfMQc_EGnsbBjnN1NdmkxxF-2qXJT_WRD_DUBvjNlzXs13YTy7oS28vmTP_9M9kqFp2Lnk36ekl7_-ajzb5WQ5mbzLKtajA2PQYPnB6zfXJzHoIvb44-9--ak9Xb9_3rk8bQlpfGGS24ZIi0lAkmKNW8k04wZITpOB3IgF0rMePaDNRgJFxHCZPMCVE3Jh09BK-ufbe7Hxs7GBvqaKPaJr_R6VJF7dX_SvBrdR4nhRHDTKKuOjy_cUjxYmdzURufjR1HHWzcZUXaedsd36MvrlFTP5uTdXd9MFJzhKpGqAhR-wgr_uzf2e7g28zoFcoBmYg</recordid><startdate>20230520</startdate><enddate>20230520</enddate><creator>Halabi, Susan</creator><creator>Yang, Qian</creator><creator>Roy, Akash</creator><creator>Luo, Bin</creator><creator>Araujo, John C</creator><creator>Logothetis, Christopher</creator><creator>Sternberg, Cora N</creator><creator>Armstrong, Andrew J</creator><creator>Carducci, Michael A</creator><creator>Chi, Kim N</creator><creator>de Bono, Johann S</creator><creator>Petrylak, Daniel P</creator><creator>Fizazi, Karim</creator><creator>Higano, Celestia S</creator><creator>Morris, Michael J</creator><creator>Rathkopf, Dana E</creator><creator>Saad, Fred</creator><creator>Ryan, Charles J</creator><creator>Small, Eric J</creator><creator>Kelly, William Kevin</creator><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5308-8972</orcidid><orcidid>https://orcid.org/0000-0003-2986-5617</orcidid><orcidid>https://orcid.org/0000-0001-7012-1754</orcidid><orcidid>https://orcid.org/0000-0002-6068-9474</orcidid><orcidid>https://orcid.org/0000-0002-2034-595X</orcidid><orcidid>https://orcid.org/0000-0003-4135-2777</orcidid><orcidid>https://orcid.org/0000-0003-2629-672X</orcidid><orcidid>https://orcid.org/0000-0002-9454-0096</orcidid><orcidid>https://orcid.org/0000-0001-6165-5797</orcidid><orcidid>https://orcid.org/0000-0003-3938-2627</orcidid><orcidid>https://orcid.org/0000-0002-8102-288X</orcidid><orcidid>https://orcid.org/0000-0002-3983-5676</orcidid><orcidid>https://orcid.org/0000-0003-3191-6268</orcidid><orcidid>https://orcid.org/0000-0002-3782-7226</orcidid></search><sort><creationdate>20230520</creationdate><title>External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer</title><author>Halabi, Susan ; Yang, Qian ; Roy, Akash ; Luo, Bin ; Araujo, John C ; Logothetis, Christopher ; Sternberg, Cora N ; Armstrong, Andrew J ; Carducci, Michael A ; Chi, Kim N ; de Bono, Johann S ; Petrylak, Daniel P ; Fizazi, Karim ; Higano, Celestia S ; Morris, Michael J ; Rathkopf, Dana E ; Saad, Fred ; Ryan, Charles J ; Small, Eric J ; Kelly, William Kevin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-fca65740283464633a597f640c6c953d2d1f87145acd3c106f932474f662007f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Docetaxel - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>ORIGINAL REPORTS</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prostatic Neoplasms, Castration-Resistant - pathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Halabi, Susan</creatorcontrib><creatorcontrib>Yang, Qian</creatorcontrib><creatorcontrib>Roy, Akash</creatorcontrib><creatorcontrib>Luo, Bin</creatorcontrib><creatorcontrib>Araujo, John C</creatorcontrib><creatorcontrib>Logothetis, Christopher</creatorcontrib><creatorcontrib>Sternberg, Cora N</creatorcontrib><creatorcontrib>Armstrong, Andrew J</creatorcontrib><creatorcontrib>Carducci, Michael A</creatorcontrib><creatorcontrib>Chi, Kim N</creatorcontrib><creatorcontrib>de Bono, Johann S</creatorcontrib><creatorcontrib>Petrylak, Daniel P</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Higano, Celestia S</creatorcontrib><creatorcontrib>Morris, Michael J</creatorcontrib><creatorcontrib>Rathkopf, Dana E</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Ryan, Charles J</creatorcontrib><creatorcontrib>Small, Eric J</creatorcontrib><creatorcontrib>Kelly, William Kevin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Halabi, Susan</au><au>Yang, Qian</au><au>Roy, Akash</au><au>Luo, Bin</au><au>Araujo, John C</au><au>Logothetis, Christopher</au><au>Sternberg, Cora N</au><au>Armstrong, Andrew J</au><au>Carducci, Michael A</au><au>Chi, Kim N</au><au>de Bono, Johann S</au><au>Petrylak, Daniel P</au><au>Fizazi, Karim</au><au>Higano, Celestia S</au><au>Morris, Michael J</au><au>Rathkopf, Dana E</au><au>Saad, Fred</au><au>Ryan, Charles J</au><au>Small, Eric J</au><au>Kelly, William Kevin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2023-05-20</date><risdate>2023</risdate><volume>41</volume><issue>15</issue><spage>2736</spage><epage>2746</epage><pages>2736-2746</pages><issn>0732-183X</issn><issn>1527-7755</issn><eissn>1527-7755</eissn><abstract>We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in specific subgroups (White, Black, Asian patients, different age groups, and specific treatments) and to classify patients into validated two and three prognostic risk groupings on the basis of the model. Data from 8,083 docetaxel-naïve mCRPC men randomly assigned on seven phase III trials were used to validate the prognostic model of OS. We assessed the predictive performance of the model by computing the time-dependent area under the receiver operating characteristic curve (tAUC) and validated the two-risk (low and high) and three-risk prognostic groups (low, intermediate, and high). The tAUC was 0.74 (95% CI, 0.73 to 0.75), and when adjusting for the first-line androgen receptor (AR) inhibitor trial status, the tAUC was 0.75 (95% CI, 0.74 to 0.76). Similar results were observed by the different racial, age, and treatment subgroups. In patients enrolled on first-line AR inhibitor trials, the median OS (months) in the low-, intermediate-, and high-prognostic risk groups were 43.3 (95% CI, 40.7 to 45.8), 27.7 (95% CI, 25.8 to 31.3), and 15.4 (95% CI, 14.0 to 17.9), respectively. Compared with the low-risk prognostic group, the hazard ratios for the high- and intermediate-risk groups were 4.3 (95% CI, 3.6 to 5.1; &lt; .0001) and 1.9 (95% CI, 1.7 to 2.1; &lt; .0001). This prognostic model for OS in docetaxel-naïve men with mCRPC has been validated using data from seven trials and yields similar results overall and across race, age, and different treatment classes. The prognostic risk groups are robust and can be used to identify groups of patients for enrichment designs and for stratification in randomized clinical trials.</abstract><cop>United States</cop><pub>Wolters Kluwer Health</pub><pmid>37040594</pmid><doi>10.1200/JCO.22.02661</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5308-8972</orcidid><orcidid>https://orcid.org/0000-0003-2986-5617</orcidid><orcidid>https://orcid.org/0000-0001-7012-1754</orcidid><orcidid>https://orcid.org/0000-0002-6068-9474</orcidid><orcidid>https://orcid.org/0000-0002-2034-595X</orcidid><orcidid>https://orcid.org/0000-0003-4135-2777</orcidid><orcidid>https://orcid.org/0000-0003-2629-672X</orcidid><orcidid>https://orcid.org/0000-0002-9454-0096</orcidid><orcidid>https://orcid.org/0000-0001-6165-5797</orcidid><orcidid>https://orcid.org/0000-0003-3938-2627</orcidid><orcidid>https://orcid.org/0000-0002-8102-288X</orcidid><orcidid>https://orcid.org/0000-0002-3983-5676</orcidid><orcidid>https://orcid.org/0000-0003-3191-6268</orcidid><orcidid>https://orcid.org/0000-0002-3782-7226</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0732-183X
ispartof Journal of clinical oncology, 2023-05, Vol.41 (15), p.2736-2746
issn 0732-183X
1527-7755
1527-7755
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10414709
source MEDLINE; American Society of Clinical Oncology Online Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Docetaxel - therapeutic use
Humans
Male
ORIGINAL REPORTS
Prognosis
Proportional Hazards Models
Prostatic Neoplasms, Castration-Resistant - pathology
Treatment Outcome
title External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T09%3A50%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=External%20Validation%20of%20a%20Prognostic%20Model%20of%20Overall%20Survival%20in%20Men%20With%20Chemotherapy-Na%C3%AFve%20Metastatic%20Castration-Resistant%20Prostate%20Cancer&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Halabi,%20Susan&rft.date=2023-05-20&rft.volume=41&rft.issue=15&rft.spage=2736&rft.epage=2746&rft.pages=2736-2746&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.22.02661&rft_dat=%3Cproquest_pubme%3E2800149509%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2800149509&rft_id=info:pmid/37040594&rfr_iscdi=true